At the news
? BULLISHIMPACT 7/10 6-K filed Jul 8, 2026 at 07:34 ET
Chemomab Therapeutics (CMMB) entered into a definitive merger agreement to be acquired by Scipher Medicine Corporation, a precision medicine company. The combined company, valued at $150 million, will operate as Scipher Medicine Corporation and trade under the ticker SCIP. Chemomab shareholders will own approximately 32% of the combined company before a concurrent $30 million PIPE. The merger is expected to close in Q4 2026.
- Combined company pre-money valuation of $150 million ($48 million for Chemomab, $102 million for Scipher, subject to adjustment for Scipher's indebtedness)
- Chemomab equity holders expected to own approximately 32% of combined company; Scipher equity holders approximately 68%, pre-PIPE
- Concurrent PIPE investment of not less than $30 million from a syndicate led by Northpond Ventures including Khosla Ventures, Blue Owl Healthcare Opportunities, and funds managed by Neuberger
- Post-merger company to focus on advancing nebokitug into a Phase 2 RA trial with AI-powered precision medicine enrollment using Scipher's PrismRA test
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access